Advances in Hormone-Based Breast Cancer Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 5 December 2026
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue will provide an opportunity for investigators to participate in a collaborative effort. Individual authors will benefit individually from combined interest in the accumulated information. Each author will reap a benefit from the fact that topics of particular interest will bring together readers that otherwise would not see related work that is published individually. Treatment differences based on histopathologic classification, tumor grade, staging (tumor size, lymph node involvement, and distant metastases), biomarker/receptor status, and molecular/genomic subtypes will be explored. The specific responses and limitations of drugs that promote DNA damage, inhibit checkpoint responses, promote retinoid responses, and inhibit PARP1 will be cosidered. Issues regarding the interactions of steroids and their receptors with drugs that limit, or in some cases improve, the response to therapy will be investigated. This Special Issue of Cancers (ISSN 2072-6694).will draw the attention of practicing physicians and investigators by presenting several concomitant perspectives in one place
The purpose of this Special Issue is to present the new insights into “Factors affecting breast cancer treatment responses.”
We welcome reviews as well as original research articles, which should be submitted by 5 December 2026.
Dr. Robert Treat Chatterton
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DNA damage
- checkpoint inhibitor
- retinoid
- PARP1
- estrogen/estrogen receptors
- androgen/androgen receptors
- glucocorticoid/glucocorticoid receptors
- tumor classification
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
